Lignocainum Hydrochloricum Wzf (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium ions needed for depolarisation. This inhibition stops the generation and propagation of nerve impulses, resulting in a reversible loss of sensation in the area where the drug is administered.

The dose of Lignocainum Hydrochloricum Wzf is determined by the prescribing clinician based on the intended route (epidural, infiltration, intrathecal), the size of the area to be anesthetised, patient weight, and clinical context. No fixed regimen is provided here; the prescriber sets the appropriate concentration and volume.

Safety data for lidocaine hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

The primary alternative to lidocaine in regional anesthesia is bupivacaine, which has a longer duration of action but a higher potential for cardiotoxicity at comparable doses. Lidocaine offers a faster onset and a more favorable safety profile for short‑duration procedures, making it the preferred choice when rapid block and quick recovery are desired.

Store the sterile solution at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and avoid freezing. Ensure that handling follows standard aseptic techniques to maintain sterility until administration.

The product is administered by qualified healthcare professionals via epidural, infiltration, or intrathecal injection. The specific technique, needle size, and injection volume are selected according to the clinical indication, patient anatomy, and the desired extent of anesthesia.

Serious adverse events include severe allergic reactions (anaphylaxis), cardiac arrhythmias such as ventricular tachycardia, central nervous system toxicity manifesting as seizures or loss of consciousness, and methemoglobinemia, which can cause cyanosis and reduced oxygen delivery. Immediate medical intervention is required if any of these occur.

The product is contraindicated in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with high‑grade atrioventricular block without a pacemaker, and individuals with severe hepatic impairment where metabolism may be compromised. Caution is also advised in patients with significant cardiac disease.